226 related articles for article (PubMed ID: 29275463)
1. Regulation of CTL Infiltration Within the Tumor Microenvironment.
Church SE; Galon J
Adv Exp Med Biol; 2017; 1036():33-49. PubMed ID: 29275463
[TBL] [Abstract][Full Text] [Related]
2. [Focus on the Immunoscore and its potential clinical implications].
El Sissy C; Marliot F; Haicheur N; Kirilovsky A; Scripcariu D; Lagorce-Pagès C; Galon J; Pagès F
Ann Pathol; 2017 Feb; 37(1):29-38. PubMed ID: 28161000
[TBL] [Abstract][Full Text] [Related]
3. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
Peske JD; Woods AB; Engelhard VH
Adv Cancer Res; 2015; 128():263-307. PubMed ID: 26216636
[TBL] [Abstract][Full Text] [Related]
4. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
5. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes.
Guo G; Wang Y; Zhou Y; Quan Q; Zhang Y; Wang H; Zhang B; Xia L
J Immunother Cancer; 2019 Jul; 7(1):179. PubMed ID: 31300050
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Resistance to Cancer Immunotherapy.
McGray AJR; Bramson J
Adv Exp Med Biol; 2017; 1036():213-227. PubMed ID: 29275474
[TBL] [Abstract][Full Text] [Related]
8. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
9. Tumor Immunology and Tumor Evolution: Intertwined Histories.
Galon J; Bruni D
Immunity; 2020 Jan; 52(1):55-81. PubMed ID: 31940273
[TBL] [Abstract][Full Text] [Related]
10. Migrating into the Tumor: a Roadmap for T Cells.
van der Woude LL; Gorris MAJ; Halilovic A; Figdor CG; de Vries IJM
Trends Cancer; 2017 Nov; 3(11):797-808. PubMed ID: 29120755
[TBL] [Abstract][Full Text] [Related]
11. From mice to humans: developments in cancer immunoediting.
Teng MW; Galon J; Fridman WH; Smyth MJ
J Clin Invest; 2015 Sep; 125(9):3338-46. PubMed ID: 26241053
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
Deng S; Sun Z; Qiao J; Liang Y; Liu L; Dong C; Shen A; Wang Y; Tang H; Fu YX; Peng H
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271164
[TBL] [Abstract][Full Text] [Related]
13. Classifying Cancers Based on T-cell Infiltration and PD-L1.
Teng MW; Ngiow SF; Ribas A; Smyth MJ
Cancer Res; 2015 Jun; 75(11):2139-45. PubMed ID: 25977340
[TBL] [Abstract][Full Text] [Related]
14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
15. [Immunology and personalized medicine in oncology].
Zinzindohoué F; Zeitoun G; Berger A; Todosi AM; Marliot F; Lagorce C; Galon J; Pagès F
Bull Cancer; 2014 Jun; 101 Suppl 1():S12-7. PubMed ID: 24966077
[TBL] [Abstract][Full Text] [Related]
16. Potassium channels of T lymphocytes take center stage in the fight against cancer.
Conforti L
J Immunother Cancer; 2017; 5():2. PubMed ID: 28105369
[TBL] [Abstract][Full Text] [Related]
17. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
19. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.
Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H
Front Immunol; 2020; 11():622509. PubMed ID: 33633741
[TBL] [Abstract][Full Text] [Related]
20. Evolution of Metastases in Space and Time under Immune Selection.
Angelova M; Mlecnik B; Vasaturo A; Bindea G; Fredriksen T; Lafontaine L; Buttard B; Morgand E; Bruni D; Jouret-Mourin A; Hubert C; Kartheuser A; Humblet Y; Ceccarelli M; Syed N; Marincola FM; Bedognetti D; Van den Eynde M; Galon J
Cell; 2018 Oct; 175(3):751-765.e16. PubMed ID: 30318143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
